Qualitative exploration of women’s experiences of vasomotor symptoms to support the content validity of patient-reported outcomes
Findings provide detailed insights into women's experience of VMS, supporting the development of a conceptual model and assessment of conceptual coverage of selected PRO measures. Content validity of the HFDD, PROMIS SD SF 8b, and MENQOL for use in VMS clinical trials was supported. CI results suggest that a reduction of one moderate or one severe hot flash in 24-hours is meaningful to women with VMS.
Authors
- Christian Seitz (ORCID: https://orcid.org/0000-0003-2315-9148)
- Helena Bradley (ORCID: https://orcid.org/0000-0002-7077-2183)
- Claudia Haberland (ORCID: https://orcid.org/0000-0002-5533-1881)
- Sophie Whyman
- Adam Gater (ORCID: https://orcid.org/0000-0001-9582-8596)
- Asha Lehane (ORCID: https://orcid.org/0000-0003-1689-569X)
- Christoph Gerlinger (ORCID: https://orcid.org/0000-0003-4538-6413)
- Melissa Barclay (ORCID: https://orcid.org/0000-0003-1822-6641)
- Maja Francuski
- Andrew Trigg (ORCID: https://orcid.org/0000-0002-1613-8042)
- Nils Schoof (ORCID: https://orcid.org/0000-0003-0343-2776)
Institutions
- Adelphi Group (United Kingdom) (GB)
- Bayer (United Kingdom) (GB)
- Bayer (Germany) (DE)
- Charité - Universitätsmedizin Berlin (DE)
- Saarland University (DE)
Publication Details
- Journal
- Journal of Patient-Reported Outcomes
- Published
- 2025-07-01
- DOI
- https://doi.org/10.1186/s41687-025-00914-0
- Primary Topic
- Menopause: Health Impacts and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Bayer